The Role of Faricimab in Extending Durability and Treating Retinal Vascular Diseases

In this segment, Dr. Harit Bhatt and Dr. Deepak Sambhara discuss the emergence of faricimab, a second-generation, dual-pathway anti-VEGF therapy targeting both VEGF-A and Ang-2. Dr. Sambhara shares his early clinical experience, describing faricimab as the first new retinal therapy he confidently adopted after the limitations of earlier agents. He highlights its mechanistic innovation and real-world impact—achieving greater durability and improved disease control, particularly in DME and RVO, where vascular leakage drives pathology. Dr. Bhatt echoes these experiences, noting that faricimab’s dual inhibition helps restore retinal stability by addressing the entire vascular environment, not just macular edema. Both clinicians emphasize its strong efficacy, safety, and flexibility compared to other agents, while also anticipating future developments such as broader labeling and prefilled syringe availability. Together, they frame faricimab as a transformative step in achieving long-lasting disease control across retinal vascular disorders.